National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Praluent® is indicated for both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.

Rapid Review

Commenced Completed Outcome
13/10/2015 02/11/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
04/01/2016  06/06/2017 Reimbursement Not Recommended

Summary

Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement.

The HSE has re-commissioned a full HTA for this product as of 20th March 2018
Full pharmacoeconomic assessment re-commissioned by HSE 20/03/2018

 

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.